[{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Repare Therapeutics","amount2":3.0699999999999998,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":3.0699999999999998,"dosageForm":"","sponsorNew":"Repare Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Repare Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"AbCellera","sponsor":"OrbiMed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Series B Financing","leadProduct":"Antibody","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0.11,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"","sponsorNew":"AbCellera \/ OrbiMed","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ OrbiMed"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"AAV-based gene therapy","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Ultragenyx Pharmaceutical","amount2":0.23000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.23000000000000001,"dosageForm":"","sponsorNew":"Ultragenyx Pharmaceutical \/ Daiichi Sankyo","highestDevelopmentStatusID":"3","companyTruncated":"Ultragenyx Pharmaceutical \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Ubiquigent","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Ubiquigent","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ubiquigent \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Ubiquigent \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Alteogen","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"ALT-B4","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Alteogen","amount2":3.8799999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":3.8799999999999999,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alteogen \/ Undisclosed","highestDevelopmentStatusID":"3","companyTruncated":"Alteogen \/ Undisclosed"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Foghorn Therapeutics","amount2":0.42999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.42999999999999999,"dosageForm":"","sponsorNew":"Foghorn Therapeutics \/ Merck","highestDevelopmentStatusID":"3","companyTruncated":"Foghorn Therapeutics \/ Merck"},{"orgOrder":0,"company":"Syracuse Biopharma","sponsor":"JW Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Cell and Gene therapy","year":"2020","type":"Acquisition","leadProduct":"T-cell therapy","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Syracuse Biopharma","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Syracuse Biopharma \/ JW Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Syracuse Biopharma \/ JW Therapeutics"},{"orgOrder":0,"company":"panCELLa","sponsor":"NRC IRAP","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"Human embryonic stem cells","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"panCELLa","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"panCELLa \/ NRC IRAP","highestDevelopmentStatusID":"3","companyTruncated":"panCELLa \/ NRC IRAP"},{"orgOrder":0,"company":"Horizon Discovery Group","sponsor":"TrueBinding","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"Chinese Hamster Ovary K1 cell","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Horizon Discovery Group","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Horizon Discovery Group \/ TrueBinding","highestDevelopmentStatusID":"3","companyTruncated":"Horizon Discovery Group \/ TrueBinding"},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Omega Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Omega Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"3","companyTruncated":"Omega Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Hangzhou Zhongmei Huadong Pharmaceutical","sponsor":"Exscientia","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Hangzhou Zhongmei Huadong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Hangzhou Zhongmei Huadong Pharmaceutical \/ Exscientia","highestDevelopmentStatusID":"3","companyTruncated":"Hangzhou Zhongmei Huadong Pharmaceutical \/ Exscientia"},{"orgOrder":0,"company":"Taurus Biosciences","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Acquisition","leadProduct":"Mono- and Bispecific human antibodies","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Taurus Biosciences","amount2":0.01,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"Taurus Biosciences \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Taurus Biosciences \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Xcella Biosciences","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Acquisition","leadProduct":"Mono- and Bispecific human antibodies","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Xcella Biosciences","amount2":0.01,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"Xcella Biosciences \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Xcella Biosciences \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"AbCellera","sponsor":"IGM Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"IgM antibodies","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ IGM Biosciences","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ IGM Biosciences"},{"orgOrder":0,"company":"GenScript Biotech Corporation","sponsor":"REMD","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Bispecific Antibody","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"GenScript Biotech Corporation","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"GenScript Biotech Corporation \/ REMD","highestDevelopmentStatusID":"3","companyTruncated":"GenScript Biotech Corporation \/ REMD"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Takara Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Takara Bio","highestDevelopmentStatusID":"3","companyTruncated":"Merck & Co \/ Takara Bio"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Bispecific Antibody","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Oxford Biotherapeutics \/ Boehringer Ingelheim","highestDevelopmentStatusID":"3","companyTruncated":"Oxford Biotherapeutics \/ Boehringer Ingelheim"},{"orgOrder":0,"company":"Eurofins Discovery","sponsor":"Amphilix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Eurofins Discovery","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Eurofins Discovery \/ Amphilix","highestDevelopmentStatusID":"3","companyTruncated":"Eurofins Discovery \/ Amphilix"},{"orgOrder":0,"company":"AbCellera","sponsor":"Invetx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Monoclonal antibody","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Invetx","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Invetx"},{"orgOrder":0,"company":"Artios Pharma Limited","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Artios Pharma Limited","amount2":6.9100000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":6.9100000000000001,"dosageForm":"","sponsorNew":"Artios Pharma Limited \/ Merck KGaA","highestDevelopmentStatusID":"3","companyTruncated":"Artios Pharma Limited \/ Merck KGaA"},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"SK Holdings","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Roivant Sciences","amount2":0.20000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.20000000000000001,"dosageForm":"","sponsorNew":"Roivant Sciences \/ SK Holdings","highestDevelopmentStatusID":"3","companyTruncated":"Roivant Sciences \/ SK Holdings"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Xencor","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Human antibody","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Biocytogen \/ Xencor","highestDevelopmentStatusID":"3","companyTruncated":"Biocytogen \/ Xencor"},{"orgOrder":0,"company":"Proxygen","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Proxygen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Proxygen \/ Boehringer Ingelheim","highestDevelopmentStatusID":"3","companyTruncated":"Proxygen \/ Boehringer Ingelheim"},{"orgOrder":0,"company":"Atomwise","sponsor":"FutuRx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Atomwise","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Atomwise \/ FutuRx","highestDevelopmentStatusID":"3","companyTruncated":"Atomwise \/ FutuRx"},{"orgOrder":0,"company":"HitGen","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"HitGen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"HitGen \/ Merck","highestDevelopmentStatusID":"3","companyTruncated":"HitGen \/ Merck"},{"orgOrder":0,"company":"Ribometrix","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"RNA-Targeted Therapeutics","moa":"RNA","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Ribometrix","amount2":1.03,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":1.03,"dosageForm":"","sponsorNew":"Ribometrix \/ Genentech","highestDevelopmentStatusID":"3","companyTruncated":"Ribometrix \/ Genentech"},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"Boxer Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Scorpion Therapeutics","amount2":0.16,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.16,"dosageForm":"","sponsorNew":"Scorpion Therapeutics \/ Boxer Capital","highestDevelopmentStatusID":"3","companyTruncated":"Scorpion Therapeutics \/ Boxer Capital"},{"orgOrder":0,"company":"Alteogen","sponsor":"Intas Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"ALT-B4","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Alteogen","amount2":0.11,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alteogen \/ Intas Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Alteogen \/ Intas Pharmaceuticals"},{"orgOrder":0,"company":"Blacksmith Medicines","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Metalloenzyme-targeted medicines","moa":"Metalloenzyme","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Blacksmith Medicines","amount2":0.29999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.29999999999999999,"dosageForm":"","sponsorNew":"Blacksmith Medicines \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Blacksmith Medicines \/ Eli Lilly"},{"orgOrder":0,"company":"Integral Molecular","sponsor":"Optimeos","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Partnership","leadProduct":"Long-acting Therapeutic antibodies","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Integral Molecular","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"sustain delivery formulation","sponsorNew":"Integral Molecular \/ Optimeos","highestDevelopmentStatusID":"3","companyTruncated":"Integral Molecular \/ Optimeos"},{"orgOrder":0,"company":"Theolytics","sponsor":"Epidarex Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Series A Financing","leadProduct":"Oncolytic viral therapy","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Theolytics","amount2":0.01,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Theolytics \/ Epidarex Capital","highestDevelopmentStatusID":"3","companyTruncated":"Theolytics \/ Epidarex Capital"},{"orgOrder":0,"company":"Sirion Biotech","sponsor":"Cellectis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"Allogeneic CAR T-cells","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Sirion Biotech","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sirion Biotech \/ Cellectis","highestDevelopmentStatusID":"3","companyTruncated":"Sirion Biotech \/ Cellectis"},{"orgOrder":0,"company":"LifeMine Therapeutics","sponsor":"Rick Klausner","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"LifeMine Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"LifeMine Therapeutics \/ Rick Klausner","highestDevelopmentStatusID":"3","companyTruncated":"LifeMine Therapeutics \/ Rick Klausner"},{"orgOrder":0,"company":"Xencor","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Bispecific antibodies","moa":"CD3","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Xencor \/ University of Texas MD Anderson","highestDevelopmentStatusID":"3","companyTruncated":"Xencor \/ University of Texas MD Anderson"},{"orgOrder":0,"company":"Enara Bio","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Enara Bio","amount2":1.0600000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":1.0600000000000001,"dosageForm":"","sponsorNew":"Enara Bio \/ Boehringer Ingelheim","highestDevelopmentStatusID":"3","companyTruncated":"Enara Bio \/ Boehringer Ingelheim"},{"orgOrder":0,"company":"Nirogy therapeutics","sponsor":"Sante Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Nirogy therapeutics","amount2":0.02,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"","sponsorNew":"Nirogy therapeutics \/ Sante Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Nirogy therapeutics \/ Sante Ventures"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"AB-MK-001","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Artiva Biotherapeutics","amount2":1.8700000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":1.8700000000000001,"dosageForm":"","sponsorNew":"Artiva Biotherapeutics \/ Merck","highestDevelopmentStatusID":"3","companyTruncated":"Artiva Biotherapeutics \/ Merck"},{"orgOrder":0,"company":"Caribou Biosciences","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"CAR-T cell therapies","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Caribou Biosciences","amount2":0.34000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.34000000000000002,"dosageForm":"","sponsorNew":"Caribou Biosciences \/ AbbVie","highestDevelopmentStatusID":"3","companyTruncated":"Caribou Biosciences \/ AbbVie"},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Molecular Templates","amount2":1.3700000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":1.3700000000000001,"dosageForm":"","sponsorNew":"Molecular Templates \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Molecular Templates \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"neoX Biotech","sponsor":"Sky9 Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"neoX Biotech","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"neoX Biotech \/ Sky9 Capital","highestDevelopmentStatusID":"3","companyTruncated":"neoX Biotech \/ Sky9 Capital"},{"orgOrder":0,"company":"Cevec","sponsor":"Carisma Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"CAR-macrophage immunotherapies","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Cevec","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Cevec \/ Carisma Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Cevec \/ Carisma Therapeutics"},{"orgOrder":0,"company":"HitGen","sponsor":"UPPTHERA","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"HitGen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"HitGen \/ UPPTHERA","highestDevelopmentStatusID":"3","companyTruncated":"HitGen \/ UPPTHERA"},{"orgOrder":0,"company":"Artios Pharma Limited","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Radioligand Therapy","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Artios Pharma Limited","amount2":1.3200000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":1.3200000000000001,"dosageForm":"","sponsorNew":"Artios Pharma Limited \/ Novartis","highestDevelopmentStatusID":"3","companyTruncated":"Artios Pharma Limited \/ Novartis"},{"orgOrder":0,"company":"Anavo Therapeutics","sponsor":"M Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Allosteric phosphatase","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Anavo Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"","sponsorNew":"Anavo Therapeutics \/ M Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Anavo Therapeutics \/ M Ventures"},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Protein degradation","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Evotec","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"RNA","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Evotec","amount2":0.16,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.16,"dosageForm":"","sponsorNew":"Evotec \/ Takeda","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ Takeda"},{"orgOrder":0,"company":"Alchemab","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Antibody-based therapeutics","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Alchemab","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Alchemab \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"Alchemab \/ AstraZeneca"},{"orgOrder":0,"company":"Proteros","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Proteros","amount2":0.070000000000000007,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Proteros \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"Proteros \/ AstraZeneca"},{"orgOrder":0,"company":"Ajax Therapeutics","sponsor":"EcoR1 Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Cytokine signaling pathways","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Ajax Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Ajax Therapeutics \/ EcoR1 Capital","highestDevelopmentStatusID":"3","companyTruncated":"Ajax Therapeutics \/ EcoR1 Capital"},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Genmab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Antibody-based Conjugate Therapy","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Bolt Biotherapeutics","amount2":0.88,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.88,"dosageForm":"","sponsorNew":"Bolt Biotherapeutics \/ Genmab","highestDevelopmentStatusID":"3","companyTruncated":"Bolt Biotherapeutics \/ Genmab"},{"orgOrder":0,"company":"Kojin Therapeutics","sponsor":"Polaris Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Series A Financing","leadProduct":"Ferroptosis-based Drug","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Kojin Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Kojin Therapeutics \/ Polaris Partners","highestDevelopmentStatusID":"3","companyTruncated":"Kojin Therapeutics \/ Polaris Partners"},{"orgOrder":0,"company":"Mnemo Therapeutics","sponsor":"Casdin Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Series A Financing","leadProduct":"CAR-T Therapy","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Mnemo Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Mnemo Therapeutics \/ Casdin Capital","highestDevelopmentStatusID":"3","companyTruncated":"Mnemo Therapeutics \/ Casdin Capital"},{"orgOrder":0,"company":"Theolytics","sponsor":"M Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Series A Financing","leadProduct":"Oncolytic Viral Therapies","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Theolytics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theolytics \/ M Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Theolytics \/ M Ventures"},{"orgOrder":0,"company":"Glycotope","sponsor":"Byondis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Glycotope","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Glycotope \/ Byondis","highestDevelopmentStatusID":"3","companyTruncated":"Glycotope \/ Byondis"},{"orgOrder":0,"company":"La Jolla Institute","sponsor":"Cytocom","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"TLR","graph1":"Oncology","graph2":"Discovery Platform","graph3":"La Jolla Institute","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"La Jolla Institute \/ Cytocom","highestDevelopmentStatusID":"3","companyTruncated":"La Jolla Institute \/ Cytocom"},{"orgOrder":0,"company":"AbCellera","sponsor":"Tachyon Technologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"TACH204","moa":"LEFTY1","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Tachyon","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Tachyon"},{"orgOrder":0,"company":"Appia Bio","sponsor":"Kite Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"HSC-derived CAR iNKT-cell Therapies","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Appia Bio","amount2":0.88,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.88,"dosageForm":"","sponsorNew":"Appia Bio \/ Kite","highestDevelopmentStatusID":"3","companyTruncated":"Appia Bio \/ Kite"},{"orgOrder":0,"company":"Invenra","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Expanded Collaboration","leadProduct":"Multi-specific Antibody","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Invenra","amount2":0.48999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.48999999999999999,"dosageForm":"","sponsorNew":"Invenra \/ Exelixis","highestDevelopmentStatusID":"3","companyTruncated":"Invenra \/ Exelixis"},{"orgOrder":0,"company":"FutureGen","sponsor":"Gracell Biotechnologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Immune Cell Therapies","moa":"CLDN18.2","graph1":"Oncology","graph2":"Discovery Platform","graph3":"FutureGen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"FutureGen \/ Gracell Biotechnologies","highestDevelopmentStatusID":"3","companyTruncated":"FutureGen \/ Gracell Biotechnologies"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Orion Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Bispecific Antibody","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Alligator Bioscience","amount2":0.55000000000000004,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.55000000000000004,"dosageForm":"","sponsorNew":"Alligator Bioscience \/ Orion Corporation","highestDevelopmentStatusID":"3","companyTruncated":"Alligator Bioscience \/ Orion Corporation"},{"orgOrder":0,"company":"Atavistik Bio","sponsor":"The Column Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Atavistik Bio","amount2":0.059999999999999998,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Atavistik Bio \/ The Column Group","highestDevelopmentStatusID":"3","companyTruncated":"Atavistik Bio \/ The Column Group"},{"orgOrder":0,"company":"TumorGen","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"TumorGen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"TumorGen \/ National Cancer Institute","highestDevelopmentStatusID":"3","companyTruncated":"TumorGen \/ National Cancer Institute"},{"orgOrder":0,"company":"Hangzhou Huadong Medicine Group Kangrun Pharmaceutical","sponsor":"Insilico Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Hangzhou Huadong Medicine Group Kangrun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Hangzhou Huadong Medicine Group Kangrun Pharmaceutical \/ Insilico Medicine","highestDevelopmentStatusID":"3","companyTruncated":"Hangzhou Huadong Medicine Group Kangrun Pharmaceutical \/ Insilico Medicine"},{"orgOrder":0,"company":"SaponiQx","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"Saponin-based Adjuvanted Vaccine","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"SaponiQx","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"SaponiQx \/ Ginkgo Bioworks","highestDevelopmentStatusID":"3","companyTruncated":"SaponiQx \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"AlivaMab","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Agreement","leadProduct":"Antibody-based Therapeutic","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AlivaMab","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"AlivaMab \/ Teva Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"AlivaMab \/ Teva Pharmaceuticals"},{"orgOrder":0,"company":"Vipergen","sponsor":"PhoreMost","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Vipergen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Vipergen \/ PhoreMost","highestDevelopmentStatusID":"3","companyTruncated":"Vipergen \/ PhoreMost"},{"orgOrder":0,"company":"Hexagon Bio","sponsor":"Nextech Invest","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Hexagon Bio","amount2":0.059999999999999998,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Hexagon Bio \/ Nextech Invest","highestDevelopmentStatusID":"3","companyTruncated":"Hexagon Bio \/ Nextech Invest"},{"orgOrder":0,"company":"AbCellera","sponsor":"Everest Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Bispecific Antibodies","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Everest Medicines","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Everest Medicines"},{"orgOrder":0,"company":"Abexxa Biologics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Acquisition","leadProduct":"Antibody","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Abexxa Biologics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Abexxa Biologics \/ Boehringer Ingelheim","highestDevelopmentStatusID":"3","companyTruncated":"Abexxa Biologics \/ Boehringer Ingelheim"},{"orgOrder":0,"company":"Outpace Bio","sponsor":"Century Therapeutic","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Engineered iPSC-based Cell Therapy","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Outpace Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Outpace Bio \/ Century Therapeutic","highestDevelopmentStatusID":"3","companyTruncated":"Outpace Bio \/ Century Therapeutic"},{"orgOrder":0,"company":"Tentarix Biotherapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Series A Financing","leadProduct":"Antibody-based Multifunctional Therapeutic","moa":"IL2R gamma receptor","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Tentarix Biotherapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Tentarix Biotherapeutics \/ Versant Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Tentarix Biotherapeutics \/ Versant Ventures"},{"orgOrder":0,"company":"Cytoreason","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Cytoreason","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Cytoreason \/ Merck","highestDevelopmentStatusID":"3","companyTruncated":"Cytoreason \/ Merck"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Ubiquigent","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Ubiquigent Limited","highestDevelopmentStatusID":"3","companyTruncated":"Bristol Myers Squibb \/ Ubiquigent Limited"},{"orgOrder":0,"company":"Tempus","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Tempus","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Tempus \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"Tempus \/ AstraZeneca"},{"orgOrder":0,"company":"Abveris","sponsor":"Twist Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Acquisition","leadProduct":"Antibody","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Abveris","amount2":0.19,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.19,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Abveris \/ Twist Bioscience","highestDevelopmentStatusID":"3","companyTruncated":"Abveris \/ Twist Bioscience"},{"orgOrder":0,"company":"HotSpot Therapeutics","sponsor":"Pivotal bioVenture Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Series C Financing","leadProduct":"Undisclosed","moa":"Cbl-b","graph1":"Oncology","graph2":"Discovery Platform","graph3":"HotSpot Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Dosage Strength\/Form","sponsorNew":"HotSpot Therapeutics \/ Pivotal bioVenture Partners","highestDevelopmentStatusID":"3","companyTruncated":"HotSpot Therapeutics \/ Pivotal bioVenture Partners"},{"orgOrder":0,"company":"Confo Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Antibody Medicines","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Confo Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Confo Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Confo Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Loxo Oncology Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Foghorn Therapeutics","amount2":0.38,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.38,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Foghorn Therapeutics \/ Loxo Oncology","highestDevelopmentStatusID":"3","companyTruncated":"Foghorn Therapeutics \/ Loxo Oncology"},{"orgOrder":0,"company":"HotSpot Therapeutics","sponsor":"Caris Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"HotSpot Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"HotSpot Therapeutics \/ Caris Life Sciences","highestDevelopmentStatusID":"3","companyTruncated":"HotSpot Therapeutics \/ Caris Life Sciences"},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Scorpion Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Scorpion Therapeutics \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"Scorpion Therapeutics \/ AstraZeneca"},{"orgOrder":0,"company":"Genocea","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"Cancer Vaccine","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Genocea","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Genocea \/ Janssen Biotech","highestDevelopmentStatusID":"3","companyTruncated":"Genocea \/ Janssen Biotech"},{"orgOrder":0,"company":"Engitix Therapeutics","sponsor":"Dompe Farmaceutici","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Engitix Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Engitix Therapeutics \/ Domp\u00e9 farmaceutici","highestDevelopmentStatusID":"3","companyTruncated":"Engitix Therapeutics \/ Domp\u00e9 farmaceutici"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Pepscan Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2022","type":"Collaboration","leadProduct":"Peptide-based Radiopharmaceutical","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Fusion Pharma \/ Pepscan Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Fusion Pharma \/ Pepscan Therapeutics"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Scripps Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bridge Biotherapeutics \/ Scripps Research","highestDevelopmentStatusID":"3","companyTruncated":"Bridge Biotherapeutics \/ Scripps Research"},{"orgOrder":0,"company":"EdiGene","sponsor":"Neukio Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"iPSC-CAR-NK Cell Therapy","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"EdiGene","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"EdiGene \/ Neukio Biotherapeutics","highestDevelopmentStatusID":"3","companyTruncated":"EdiGene \/ Neukio Biotherapeutics"},{"orgOrder":0,"company":"Argobio","sponsor":"Oncode Bridge Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Protein","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Argobio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Argobio \/ Oncode Bridge Fund","highestDevelopmentStatusID":"3","companyTruncated":"Argobio \/ Oncode Bridge Fund"},{"orgOrder":0,"company":"Plexium","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Plexium","amount2":0.5,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.5,"dosageForm":"","sponsorNew":"Plexium \/ Amgen","highestDevelopmentStatusID":"3","companyTruncated":"Plexium \/ Amgen"},{"orgOrder":0,"company":"ImmunoScape","sponsor":"Pure MHC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"TCR-T Therapeutics","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"ImmunoScape","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"ImmunoScape \/ Pure MHC","highestDevelopmentStatusID":"3","companyTruncated":"ImmunoScape \/ Pure MHC"},{"orgOrder":0,"company":"Arrakis Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Arrakis Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Arrakis Therapeutics \/ Amgen Inc","highestDevelopmentStatusID":"3","companyTruncated":"Arrakis Therapeutics \/ Amgen Inc"},{"orgOrder":0,"company":"GigaMune","sponsor":"Champions Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"T-cell Therapy","moa":"T-cell receptor","graph1":"Oncology","graph2":"Discovery Platform","graph3":"GigaMune","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"GigaMune \/ Champions Oncology","highestDevelopmentStatusID":"3","companyTruncated":"GigaMune \/ Champions Oncology"},{"orgOrder":0,"company":"Medigene","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"TCR Immunotherapy","moa":"T-cell receptor","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Medigene \/ BioNTech","highestDevelopmentStatusID":"3","companyTruncated":"Medigene \/ BioNTech"},{"orgOrder":0,"company":"Plexium","sponsor":"BVF Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"IKZF2 transcription factor","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Plexium","amount2":0.10000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Plexium \/ BVF Partners","highestDevelopmentStatusID":"3","companyTruncated":"Plexium \/ BVF Partners"},{"orgOrder":0,"company":"Xcell Biosciences","sponsor":"Casdin Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Xcell Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Xcell Biosciences \/ Casdin Capital","highestDevelopmentStatusID":"3","companyTruncated":"Xcell Biosciences \/ Casdin Capital"},{"orgOrder":0,"company":"NextRNA Therapeutics","sponsor":"Cobro Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Financing","leadProduct":"Non-coding RNA-directed Medicine","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"NextRNA Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"NextRNA Therapeutics \/ Cobro Ventures","highestDevelopmentStatusID":"3","companyTruncated":"NextRNA Therapeutics \/ Cobro Ventures"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Antibody","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Numab Therapeutics","amount2":0.28000000000000003,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.28000000000000003,"dosageForm":"","sponsorNew":"Numab Therapeutics \/ Ono Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Numab Therapeutics \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Vipergen","sponsor":"Theseus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"TYK","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Vipergen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Vipergen \/ Theseus Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Vipergen \/ Theseus Pharmaceuticals"},{"orgOrder":0,"company":"Alloy Therapeutics","sponsor":"Tegmine Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Antibody-based Therapeutic","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Alloy Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Alloy Therapeutics \/ Tegmine Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Alloy Therapeutics \/ Tegmine Therapeutics"},{"orgOrder":0,"company":"EdiGene","sponsor":"Peking University Cancer Hospital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"EdiGene","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"EdiGene \/ Peking University Cancer Hospital","highestDevelopmentStatusID":"3","companyTruncated":"EdiGene \/ Peking University Cancer Hospital"},{"orgOrder":0,"company":"AbCellera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"CD3","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Not Applicable","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Not Applicable"},{"orgOrder":0,"company":"Biocytogen","sponsor":"CtM Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"TCR-mimic Antibody","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Biocytogen \/ CtM Biotech","highestDevelopmentStatusID":"3","companyTruncated":"Biocytogen \/ CtM Biotech"},{"orgOrder":0,"company":"Biocytogen","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Bispecific Antibody","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Biocytogen \/ BeiGene","highestDevelopmentStatusID":"3","companyTruncated":"Biocytogen \/ BeiGene"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Engineered IgM Antibody","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"IGM Biosciences","amount2":6.1500000000000004,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":6.1699999999999999,"dosageForm":"","sponsorNew":"IGM Biosciences \/ Sanofi","highestDevelopmentStatusID":"3","companyTruncated":"IGM Biosciences \/ Sanofi"},{"orgOrder":0,"company":"Shoreline Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"iPSC-NK Cells","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Shoreline Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Shoreline Biosciences \/ Not Applicable","highestDevelopmentStatusID":"3","companyTruncated":"Shoreline Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Terremoto Biosciences","sponsor":"OrbiMed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Series A Financing","leadProduct":"Lysine-targeted Covalent Therapy","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Terremoto Biosciences","amount2":0.080000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Terremoto Biosciences \/ OrbiMed","highestDevelopmentStatusID":"3","companyTruncated":"Terremoto Biosciences \/ OrbiMed"},{"orgOrder":0,"company":"Frame Cancer Therapeutics","sponsor":"CureVac","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Acquisition","leadProduct":"mRNA Cancer Vaccine","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Frame Cancer Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Frame Cancer Therapeutics \/ CureVac","highestDevelopmentStatusID":"3","companyTruncated":"Frame Cancer Therapeutics \/ CureVac"},{"orgOrder":0,"company":"BioInvent","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BioInvent \/ Exelixis","highestDevelopmentStatusID":"3","companyTruncated":"BioInvent \/ Exelixis"},{"orgOrder":0,"company":"VeriSIM","sponsor":"Mayo Clinic","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"VeriSIM","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"VeriSIM \/ Mayo Clinic","highestDevelopmentStatusID":"3","companyTruncated":"VeriSIM \/ Mayo Clinic"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Ildong Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"VHH Antibody","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Twist Bioscience \/ Ildong Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ Ildong Pharmaceutical"},{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"Peptilogics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"GPCR","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Orion Biotechnology","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Orion Biotechnology \/ Peptilogics","highestDevelopmentStatusID":"3","companyTruncated":"Orion Biotechnology \/ Peptilogics"},{"orgOrder":0,"company":"GenScript ProBio","sponsor":"DAAN Bio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"GenScript ProBio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"GenScript ProBio \/ DAAN Bio Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"GenScript ProBio \/ DAAN Bio Therapeutics"},{"orgOrder":0,"company":"Artizan Bioscience","sponsor":"University Medical Center Utrecht","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Artizan Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Artizan Bioscience \/ University Medical Center Utrecht","highestDevelopmentStatusID":"3","companyTruncated":"Artizan Bioscience \/ University Medical Center Utrecht"},{"orgOrder":0,"company":"AbCellera","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Antibody Therapy","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Versant Ventures","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Versant Ventures"},{"orgOrder":0,"company":"Vicinitas Therapeutics","sponsor":"16z","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"WEE1 kinase","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Vicinitas Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Vicinitas Therapeutics \/ 16z","highestDevelopmentStatusID":"3","companyTruncated":"Vicinitas Therapeutics \/ 16z"},{"orgOrder":0,"company":"GluBio Therapeutics","sponsor":"Qiming Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Protein","graph1":"Oncology","graph2":"Discovery Platform","graph3":"GluBio Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"","sponsorNew":"GluBio Therapeutics \/ Qiming Venture Partners","highestDevelopmentStatusID":"3","companyTruncated":"GluBio Therapeutics \/ Qiming Venture Partners"},{"orgOrder":0,"company":"LifeMine Therapeutics","sponsor":"Fidelity Management & Research Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Series C Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"LifeMine Therapeutics","amount2":0.17999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"LifeMine Therapeutics \/ Fidelity Management & Research Company","highestDevelopmentStatusID":"3","companyTruncated":"LifeMine Therapeutics \/ Fidelity Management & Research Company"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"BAMF","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Radioisotopes-based Therapeutic","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Isotope Technologies Munich \/ BAMF","highestDevelopmentStatusID":"3","companyTruncated":"Isotope Technologies Munich \/ BAMF"},{"orgOrder":0,"company":"ImmunoScape","sponsor":"Anzu Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Financing","leadProduct":"TCR-T-cell Therapy","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"ImmunoScape","amount2":0.01,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"ImmunoScape \/ Anzu Partners","highestDevelopmentStatusID":"3","companyTruncated":"ImmunoScape \/ Anzu Partners"},{"orgOrder":0,"company":"Cytoreason","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Cytoreason","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Cytoreason \/ Pfizer","highestDevelopmentStatusID":"3","companyTruncated":"Cytoreason \/ Pfizer"},{"orgOrder":0,"company":"Bonum Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Acquisition","leadProduct":"PD-1-targeted IL-2 Therapy","moa":"PD-1 inhibitor\/IL-2 receptor","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Bonum Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bonum Therapeutics \/ Roche","highestDevelopmentStatusID":"3","companyTruncated":"Bonum Therapeutics \/ Roche"},{"orgOrder":0,"company":"SyntheX labs","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"SyntheX labs","amount2":0.55000000000000004,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.55000000000000004,"dosageForm":"","sponsorNew":"SyntheX labs \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"SyntheX labs \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"AbCellera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"CD3","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Not Applicable","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Not Applicable"},{"orgOrder":0,"company":"Talem Therapeutics","sponsor":"OmniAb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"OmniChicken-derived Antibody","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Talem Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Talem Therapeutics \/ OmniAb","highestDevelopmentStatusID":"3","companyTruncated":"Talem Therapeutics \/ OmniAb"},{"orgOrder":0,"company":"Tavros Therapeutics","sponsor":"Vividion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Tavros Therapeutics","amount2":0.45000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.45000000000000001,"dosageForm":"","sponsorNew":"Tavros Therapeutics \/ Vividion Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Tavros Therapeutics \/ Vividion Therapeutics"},{"orgOrder":0,"company":"Tempus","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Tempus","amount2":0.070000000000000007,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Tempus \/ GSK","highestDevelopmentStatusID":"3","companyTruncated":"Tempus \/ GSK"},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"University of Pennsylvania","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"CAR-T Cell Therapy","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Candel Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Candel Therapeutics \/ University of Pennsylvania","highestDevelopmentStatusID":"3","companyTruncated":"Candel Therapeutics \/ University of Pennsylvania"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"mRNA-based Therapeutic","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nona Biosciences \/ Moderna","highestDevelopmentStatusID":"3","companyTruncated":"Nona Biosciences \/ Moderna"},{"orgOrder":0,"company":"Bonum Therapeutics","sponsor":"Roche Venture Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Series A Financing","leadProduct":"PDL1 Dependent INF-alpha Therapy","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Bonum Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Bonum Therapeutics \/ Roche Venture Fund","highestDevelopmentStatusID":"3","companyTruncated":"Bonum Therapeutics \/ Roche Venture Fund"},{"orgOrder":0,"company":"Normunity","sponsor":"Alloy Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Antibody","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Normunity","amount2":0.070000000000000007,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Normunity \/ Alloy Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Normunity \/ Alloy Therapeutics"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"IASO Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Umoja Biopharma","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Umoja Biopharma \/ IASO Bio","highestDevelopmentStatusID":"3","companyTruncated":"Umoja Biopharma \/ IASO Bio"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Dragonfly Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Bispecific Antibody","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nona Biosciences \/ Dragonfly Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Nona Biosciences \/ Dragonfly Therapeutics"},{"orgOrder":0,"company":"Turbine","sponsor":"MSD Global Health Innovation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Turbine","amount2":0.02,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"","sponsorNew":"Turbine \/ MSD Global Health Innovation","highestDevelopmentStatusID":"3","companyTruncated":"Turbine \/ MSD Global Health Innovation"},{"orgOrder":0,"company":"XtalPi","sponsor":"CK Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"XtalPi","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"XtalPi \/ CK Life Sciences","highestDevelopmentStatusID":"3","companyTruncated":"XtalPi \/ CK Life Sciences"},{"orgOrder":0,"company":"Biocytogen","sponsor":"ADC Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Biocytogen \/ ADC Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Biocytogen \/ ADC Therapeutics"},{"orgOrder":0,"company":"LabGenius","sponsor":"Innovate UK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Funding","leadProduct":"Antibody-based Therapy","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"LabGenius","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"LabGenius \/ Innovate UK","highestDevelopmentStatusID":"3","companyTruncated":"LabGenius \/ Innovate UK"},{"orgOrder":0,"company":"Eigen Therapeutics","sponsor":"Josh Kopelman","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Eigen Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"Eigen Therapeutics \/ Josh Kopelman","highestDevelopmentStatusID":"3","companyTruncated":"Eigen Therapeutics \/ Josh Kopelman"},{"orgOrder":0,"company":"Crown Bioscience","sponsor":"ERS Genomics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Crown Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Crown Bioscience \/ ERS Genomics","highestDevelopmentStatusID":"3","companyTruncated":"Crown Bioscience \/ ERS Genomics"},{"orgOrder":0,"company":"Optieum Biotechnologies","sponsor":"GI CELL","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"CAR-NK cells","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Optieum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Optieum Biotechnologies \/ GI CELL","highestDevelopmentStatusID":"3","companyTruncated":"Optieum Biotechnologies \/ GI CELL"},{"orgOrder":0,"company":"Alternative Bio","sponsor":"F-Prime Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Alternative Bio","amount2":0.02,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"","sponsorNew":"Alternative Bio \/ F-Prime Capital","highestDevelopmentStatusID":"3","companyTruncated":"Alternative Bio \/ F-Prime Capital"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"RenNano","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Biocytogen \/ Not Applicable","highestDevelopmentStatusID":"3","companyTruncated":"Biocytogen \/ Not Applicable"},{"orgOrder":0,"company":"Blacksmith Medicines","sponsor":"Forge Therapeutics, Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Merger","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Blacksmith Medicines","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Blacksmith Medicines \/ Forge Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Blacksmith Medicines \/ Forge Therapeutics"},{"orgOrder":0,"company":"Caris Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Caris Life Sciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Caris Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"3","companyTruncated":"Caris Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"RenNano","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Biocytogen \/ Not Applicable","highestDevelopmentStatusID":"3","companyTruncated":"Biocytogen \/ Not Applicable"},{"orgOrder":0,"company":"Atavistik Bio","sponsor":"Plex Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Atavistik Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Atavistik Bio \/ Plex Research","highestDevelopmentStatusID":"3","companyTruncated":"Atavistik Bio \/ Plex Research"},{"orgOrder":0,"company":"Remix Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Remix Therapeutics","amount2":1.05,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":1.05,"dosageForm":"","sponsorNew":"Remix Therapeutics \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Remix Therapeutics \/ Janssen Pharmaceutical"},{"orgOrder":0,"company":"Curve Therapeutics","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"HIF-1","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Curve Therapeutics","amount2":1.7,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":1.7,"dosageForm":"","sponsorNew":"Curve Therapeutics \/ MSD","highestDevelopmentStatusID":"3","companyTruncated":"Curve Therapeutics \/ MSD"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Engineered IgM Antibody","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"IGM Biosciences","amount2":6.1699999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":6.1699999999999999,"dosageForm":"","sponsorNew":"IGM Biosciences \/ Sanofi","highestDevelopmentStatusID":"3","companyTruncated":"IGM Biosciences \/ Sanofi"},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Bispecific Antibody","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"CytomX Therapeutics","amount2":2.0299999999999998,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":2.0299999999999998,"dosageForm":"","sponsorNew":"CytomX Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"CytomX Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Twelve Bio","sponsor":"Ensoma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Twelve Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Twelve Bio \/ Ensoma","highestDevelopmentStatusID":"3","companyTruncated":"Twelve Bio \/ Ensoma"},{"orgOrder":0,"company":"Eurofins Discovery","sponsor":"Invasight","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Eurofins Discovery","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Eurofins Discovery \/ Invasight","highestDevelopmentStatusID":"3","companyTruncated":"Eurofins Discovery \/ Invasight"},{"orgOrder":0,"company":"Hexagon Bio","sponsor":"The Column Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Hexagon Bio","amount2":0.080000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Hexagon Bio \/ The Column Group","highestDevelopmentStatusID":"3","companyTruncated":"Hexagon Bio \/ The Column Group"},{"orgOrder":0,"company":"BioMed X","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"T Cell Therapy","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"BioMed X","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BioMed X \/ Not Applicable","highestDevelopmentStatusID":"3","companyTruncated":"BioMed X \/ Not Applicable"},{"orgOrder":0,"company":"Tempus","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Tempus","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Tempus \/ Pfizer Inc","highestDevelopmentStatusID":"3","companyTruncated":"Tempus \/ Pfizer Inc"},{"orgOrder":0,"company":"Caris Life Sciences","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Caris Life Sciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Caris Life Sciences \/ Incyte Corporation","highestDevelopmentStatusID":"3","companyTruncated":"Caris Life Sciences \/ Incyte Corporation"},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Evotec","amount2":5.2000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":5.2000000000000002,"dosageForm":"","sponsorNew":"Evotec \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"EpiBiologics","sponsor":"Mubadala Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Series A Financing","leadProduct":"Bifunctional Antibody","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"EpiBiologics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"EpiBiologics \/ Mubadala Capital","highestDevelopmentStatusID":"3","companyTruncated":"EpiBiologics \/ Mubadala Capital"},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Evotec","amount2":5.2000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":5.2000000000000002,"dosageForm":"","sponsorNew":"Evotec \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Anavo Therapeutics","sponsor":"MRL Ventures Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Anavo Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Anavo Therapeutics \/ MRL Ventures Fund","highestDevelopmentStatusID":"3","companyTruncated":"Anavo Therapeutics \/ MRL Ventures Fund"},{"orgOrder":0,"company":"Artisan Bio","sponsor":"BrightPath Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"Allogeneic iNKT Cell Therapy","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Artisan Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Artisan Bio \/ BrightPath Biotherapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Artisan Bio \/ BrightPath Biotherapeutics"},{"orgOrder":0,"company":"MaxCyte","sponsor":"Walking Fish Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"B Cell-based Therapeutic","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"MaxCyte","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"MaxCyte \/ Walking Fish Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"MaxCyte \/ Walking Fish Therapeutics"},{"orgOrder":0,"company":"Transgene","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2023","type":"Termination","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Transgene \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"Transgene \/ AstraZeneca"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"PharmaEssentia","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nona Biosciences \/ PharmaEssentia","highestDevelopmentStatusID":"3","companyTruncated":"Nona Biosciences \/ PharmaEssentia"},{"orgOrder":0,"company":"HitGen","sponsor":"ARase Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"HitGen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"HitGen \/ ARase Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"HitGen \/ ARase Therapeutics"},{"orgOrder":0,"company":"Hopewell Therapeutics","sponsor":"Mass Ave Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Financing","leadProduct":"LNPmRNA-based Genetic Medicine","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Hopewell Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Hopewell Therapeutics \/ Mass Ave Capital","highestDevelopmentStatusID":"3","companyTruncated":"Hopewell Therapeutics \/ Mass Ave Capital"},{"orgOrder":0,"company":"Future Fields","sponsor":"Jenthera Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"CRISPR Based Ribonucleoprotein","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Future Fields","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Future Fields \/ Jenthera Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Future Fields \/ Jenthera Therapeutics"},{"orgOrder":0,"company":"EvolveImmune Therapeutics","sponsor":"University of Oxford","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"EvolveImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"EvolveImmune Therapeutics \/ University of Oxford","highestDevelopmentStatusID":"3","companyTruncated":"EvolveImmune Therapeutics \/ University of Oxford"},{"orgOrder":0,"company":"Cereius","sponsor":"Solve Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Radionuclide Therapeutic","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Cereius","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Cereius \/ Solve Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Cereius \/ Solve Therapeutics"},{"orgOrder":0,"company":"4SR Biosciences","sponsor":"hC Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Acquisition","leadProduct":"tRNA-based Therapeutic","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"4SR Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"4SR Biosciences \/ hC Bioscience","highestDevelopmentStatusID":"3","companyTruncated":"4SR Biosciences \/ hC Bioscience"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Imugene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Oncolytic Virus Therapy","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"RenovoRx","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"RenovoRx \/ Imugene","highestDevelopmentStatusID":"3","companyTruncated":"RenovoRx \/ Imugene"},{"orgOrder":0,"company":"EpiBiologics","sponsor":"Digitalis Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Series A Financing","leadProduct":"Bispecific Antibody","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"EpiBiologics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"EpiBiologics \/ Digitalis Ventures","highestDevelopmentStatusID":"3","companyTruncated":"EpiBiologics \/ Digitalis Ventures"},{"orgOrder":0,"company":"Nexo Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticAre
